Portal de Periódicos da CAPES

Problems and solutions in myoblast transfer therapy

2001; Wiley; Volume: 5; Issue: 1 Linguagem: Inglês

10.1111/j.1582-4934.2001.tb00136.x

1582-4934

Gayle M. Smythe, Stuart I. Hodgetts, Miranda D. Grounds,

CAR-T cell therapy research

Abstract Duchenne muscular dystrophy is a severe X‐linked neuromuscular disease that affects approximately 1/3500 live male births in every human population, and is caused by a mutation in the gene that encodes the muscle protein dystrophin. The characterization and cloning of the dystrophin gene in 1987 was a major breakthrough and it was considered that simple replacement of the dystrophin gene would ameliorate the severe and progressive skeletal muscle wasting characteristic of Duchenne muscular dystrophy. After 20 years, attempts at replacing the dystrophin gene either experimentally or clinically have met with little success, but there have been many significant advances in understanding the factors that limit the delivery of a normal dystrophin gene into dystrophic host muscle. This review addresses the host immune response and donor myoblast changes underlying some of the major problems associated with myoblast‐mediated dystrophin replacement, presents potential solutions, and outlines other novel therapeutic approaches.